The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

That's less impressive than the 50% reduction in death in Merck's KEYNOTE-189 trial of Keytruda in non-squamous NSCLC – which was behind its approval for first-line NSCLC alongside chemo in 2018 ...

During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...

San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...

Non-small cell cancer (NSCLC) tumor markers are signs of specific ... and cytokeratin 5/6 to help differentiate between adenocarcinoma and squamous cell carcinoma. Doctors may also use tumor ...

In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

In combination with chemotherapy as first-line treatment of patients with metastatic squamous and non-squamous NSCLC; For the treatment of patients with unresectable Stage III NSCLC whose disease has ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...